Zhou Kefei - Amgen Inc | 人才画像

基本信息

浏览量：4

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 27 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Abstract 3641: Pharmacodynamic and predictive biomarker results from the phase I dose escalation study of NGM707, an ILT2/ILT4 dual antagonist antibody, in patients with advanced solid tumors

Lisa K. Blum,Hung-I H. Chen,Anushka De Costa,Anjushree Iyer,Geoffrey W. Stone, Nicole D. Galicia,Jerry Chan, Brenda Dampier, Katherine Wu,Ursula Jeffry,Kefei Zhou,Joanne Sloan-Lancaster, Dhiraj Abhayankar,Vladimir Hanes,Hsiao D. Lieu,Daniel D. Kaplan,Julie M. Roda

Cancer Research（2024）

引用0浏览0引用

Pharmacodynamic and Predictive Biomarker Results from the Phase I Dose Escalation Study of NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Patients with Advanced Solid Tumors

Lisa K. Blum, Hung-I H. Chen,Anushka De Costa,Anjushree Iyer,Geoffrey W. Stone, Nicole D. Galicia,Jerry Chan, Brenda Dampier,Katherine Wu,Ursula Jeffry,Kefei Zhou,Joanne Sloan-Lancaster, Dhiraj Abhayankar,Vladimir Hanes,Hsiao D. Lieu,Daniel D. Kaplan,Julie M. Roda

CANCER RESEARCHno. 6 (2024)

引用0浏览0引用

NGM707 in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors: Preliminary Results from Dose Escalation

Judy S. Wang,Manish R. Sharma,William J. Edenfield,Kartik Sehgal, Do-Youn Oh, Yixing Jiang,Joel Michalski,Jeeyun Lee,Hans Hammers,Li-Yuan Bai, Chih-Hung Hsu, Brenda Dampier,Kefei Zhou,Li Yan,Lisa K. Blum,Joanne Sloan-Lancaster,Daniel D. Kaplan,Dhiraj Abhyankar,Hsiao D. Lieu,Vladimir Hanes,Aung Naing

CANCER RESEARCHno. 7 (2024)

引用0浏览0引用

Phase 1/2 Study of NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Advanced Solid Tumors: Interim Results from Dose-Escalation

Judy S. Wang,David Sommerhalder,Manish Sharma,William Jeffery Edenfield,Kartik Sehgal,Do-Youn Oh,Yixing Jiang,Joel Michalski,Jeeyun Lee,Hans J. Hammers,Li-Yuan Bai,Chih-Hung Hsu, Brenda A. P. Dampier,Kefei Zhou,Lisa K. Blum,Joanne Sloan Lancaster,Dhiraj J. Abhyankar,Hsiao D. Lieu,Vladimir Hanes,Aung Naing

Journal of Clinical Oncologyno. 16_suppl (2024): 2582-2582

引用0浏览0引用

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study of the Efficacy and Safety of Velusetrag in Subjects with Diabetic or Idiopathic Gastroparesis

Thomas L. Abell,Braden Kuo,Tuba Esfandyari,Nathan D. Pfeifer,Maria Grimaldi,Cecilia Renzulli, Raffaella Tacchi,Kefei Zhou,Chris N. Barnes,Deanna D. Nguyen,Linda Nguyen,Nicholas J. Talley,Richard McCallum

NEUROGASTROENTEROLOGY AND MOTILITY（2023）

引用1浏览0WOS引用

Abstract PR006: Initial Results of a Cohort of Advanced Pancreatic Cancer Patients in a Phase 1b Study of NGM120, a First-in-class Anti-Gdnf Family Receptor Alpha Like (GFRAL) Antibody

Andrew Hendifar,Efrat Dotan,Benjamin Weinberg,Edward Kim,Peter Hosein, Jian Luo,Jiping Zha,Alex DePaoli,Vladimir Hanes, Cecilia Tranmuchowski,Kefei Zhou, Carol Tseng,Hsiao Lieu

Cancer Researchno. 22_Supplement (2022)

引用0浏览0引用

Quantitative Methods for Blinded Safety Monitoring

Melvin Munsaka,Kefei Zhou

Quantitative Drug Safety and Benefit-Risk Evaluationpp.119-132, (2021)

引用0浏览0引用

Visual Analytics of Safety and Benefit-Risk from Clinical Trial Data

Melvin Munsaka,Kefei Zhou,Krishan Singh, Michael Colopy, Chen Chen, Meng Liu

Quantitative Drug Safety and Benefit-Risk Evaluationpp.351-373, (2021)

引用0浏览0引用

Minimal Residual Disease Status As a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis

Herve Avet-Loiseau,Heinz Ludwig,Ola Landgren,Bruno Paiva,Chris Morris,Hui Yang,Kefei Zhou,Sunhee Ro,Maria-Victoria Mateos

Clinical lymphoma myeloma & leukemia/Clinical lymphoma, myeloma and leukemia（2020）

引用66浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn